Cargando…

Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin

α-Mangostin is a natural product commonly used in Asia for cosmetic and medicinal applications including topical treatment of acne and skin cancer. Towards finding new pharmacological strategies that overcome NRAS mutant melanoma, we performed a cell proliferation-based combination screen using a co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Yun, Li, Ying, Westover, Kenneth D., Sun, Jiaming, Chen, Hongxiang, Zhang, Jianming, Fisher, David E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859503/ https://www.ncbi.nlm.nih.gov/pubmed/27152946 http://dx.doi.org/10.1371/journal.pone.0155217

Ejemplares similares

α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid
por: Xia, Yun, et al.
Publicado: (2016)

NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

α-Mangostin Suppresses Melanoma Growth, Migration, and Invasion and Potentiates the Anti-tumor Effect of Chemotherapy
por: Xie, Yuxiu, et al.
Publicado: (2023)

Playing POLO-like kinase in NRAS mutant melanoma
por: Chen, Hsin-Yi, et al.
Publicado: (2015)

NRAS-mutant melanoma: current challenges and future prospect
por: Muñoz-Couselo, Eva, et al.
Publicado: (2017)

Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021)

Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell Lines
por: Appleton, Kathryn M., et al.
Publicado: (2021)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Efficacy of Targeted Radionuclide Therapy Using [(131)I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
por: Akil, Hussein, et al.
Publicado: (2021)

α-Mangostin Nanoparticles Cytotoxicity and Cell Death Modalities in Breast Cancer Cell Lines
por: Herdiana, Yedi, et al.
Publicado: (2021)

Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma
por: Reyes-Uribe, Patricia, et al.
Publicado: (2018)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2017)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
por: Murphy, Brandon M., et al.
Publicado: (2022)

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
por: Dietsch, Bianca, et al.
Publicado: (2023)

Induction of Apoptosis and Inhibition of Epithelial Mesenchymal Transition by α-Mangostin in MG-63 Cell Lines
por: Park, Sung-Jin, et al.
Publicado: (2018)

Inhibition of Axl Promotes the Therapeutic Effect of Targeted Inhibition of the PI3K/Akt Pathway in NRAS Mutant Melanoma Cells
por: Gao, Xuejun, et al.
Publicado: (2022)

MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
por: Vu, Ha Linh, et al.
Publicado: (2015)

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
por: Schuler, Martin, et al.
Publicado: (2022)

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy
por: Cristofani, Riccardo, et al.
Publicado: (2022)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

The Effect of α-Mangostin and Cisplatin on Ovarian Cancer Cells and the Microenvironment
por: Borzdziłowska, Paulina, et al.
Publicado: (2022)

α, γ-Mangostins Induce Autophagy and Show Synergistic Effect with Gemcitabine in Pancreatic Cancer Cell Lines
por: Kim, Myoungjae, et al.
Publicado: (2017)

A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities
por: Bok, Ilah, et al.
Publicado: (2021)

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
por: Sanlorenzo, Martina, et al.
Publicado: (2018)

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib
por: KieΔling, Michael K., et al.
Publicado: (2017)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

α-Mangostin Extraction from the Native Mangosteen (Garcinia mangostana L.) and the Binding Mechanisms of α-Mangostin to HSA or TRF
por: Guo, Ming, et al.
Publicado: (2016)

in Vitro and in Vivo Inhibitory Effects of α-Mangostin on Cholangiocarcinoma Cells and Allografts
por: Aukkanimart, Ratchadawan, et al.
Publicado: (2017)

Nanoparticle Drug Delivery Systems for α-Mangostin
por: Wathoni, Nasrul, et al.
Publicado: (2020)

Senescent bone marrow microenvironment promotes Nras-mutant leukemia
por: Zhou, Peiqing, et al.
Publicado: (2020)

Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015)

Chromatin state profiling reveals PRC2 inhibition as a therapeutic target in NRAS–mutant melanoma
por: Terranova, Christopher J.
Publicado: (2021)

HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-Mutant Melanoma
por: Parris, Joshua L.D., et al.
Publicado: (2021)

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF
por: Gutierrez-Prat, Nuria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nv7g1143khe7upakvsirrejrg9